Lurbinectedin's Molecular Target: Implications for DNA Repair
Lurbinectedin, a synthetic tetrahydroisoquinoline derivative, has been shown to interfere with DNA repair mechanisms, making cancer cells more susceptible to DNA damage and subsequent cell death. [1] At the molecular level, lurbinectedin targets the RNA-binding protein (RBP) that binds to DNA repair factors, leading to their degradation and inhibition of repair processes.
Mechanism of Action: Disruption of RNA-Based Regulation
Lurbinectedin specifically binds to RBPs that regulate the expression of genes involved in nucleotide excision repair (NER), a critical DNA repair pathway. By binding to these RBPs, lurbinectedin disrupts the RNA-based regulation of these genes, leading to their downregulation. [2] This results in reduced levels of NER enzymes, such as XPA, XPC, and XPD, which are essential for repairing DNA damage caused by ultraviolet (UV) light and other forms of radiation.
Consequences of Impaired DNA Repair
The impairment of DNA repair mechanisms by lurbinectedin results in accumulation of DNA damage in cancer cells, making them more vulnerable to chemotherapy-induced DNA damage. [3] Additionally, the disruption of NER pathways can also lead to increased genomic instability, further contributing to the cytotoxic effects of lurbinectedin.
Comparison with Other DNA Repair Inhibitors
Lurbinectedin's mechanism of action differs from other DNA repair inhibitors, such as poly (ADP-ribose) polymerase (PARP) inhibitors, which target a distinct set of DNA repair pathways. [4] PARP inhibitors, like olaparib, target base excision repair (BER) pathways, whereas lurbinectedin targets NER pathways.
Clinical Relevance and Future Directions
The unique mechanism of action of lurbinectedin makes it an attractive candidate for treating cancer, particularly in combination with chemotherapy agents that induce DNA damage. Ongoing clinical trials are investigating lurbinectedin's efficacy in various cancer types, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Sources
[1] DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/Drug/1010/Lurbinectedin
[2] Wang, J., et al. (2020). Lurbinectedin: A new mechanism of action in cancer therapy. Journal of Experimental & Clinical Cancer Research, 39(1), 1-11. doi: 10.1186/s13046-020-01562-4
[3] Li, S., et al. (2019). Lurbinectedin induces DNA damage and synergizes with chemotherapy in non-small cell lung cancer cells. Molecular Cancer Therapeutics, 18(10), 1826-1836. doi: 10.1158/1535-7163.MCT-19-0075
[4] DrugPatentWatch.com. (n.d.). PARP inhibitors. Retrieved from https://www.drugpatentwatch.com/DrugClass/300/PARP+Inhibitors
Sources Listed
1. Wang, J., et al. (2020). Lurbinectedin: A new mechanism of action in cancer therapy. Journal of Experimental & Clinical Cancer Research, 39(1), 1-11.
2. Li, S., et al. (2019). Lurbinectedin induces DNA damage and synergizes with chemotherapy in non-small cell lung cancer cells. Molecular Cancer Therapeutics, 18(10), 1826-1836.
3. DrugPatentWatch.com. (n.d.). Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/Drug/1010/Lurbinectedin
4. DrugPatentWatch.com. (n.d.). PARP inhibitors. Retrieved from https://www.drugpatentwatch.com/DrugClass/300/PARP+Inhibitors